Management of Invasive Candidiasis in the Critically Ill

  • J. Garnacho-Montero
  • A. Díaz-Martín
  • J. A. Márquez-Vácaro
Part of the Annual Update in Intensive Care and Emergency Medicine book series (AUICEM, volume 2012)


In the last few decades, fungi have become one of the most important and frequent opportunistic microorganisms involved in nosocomial infections in hospitalized patients. The most common organism implicated in fungal infections is the ubiquitous Candida, which is part of the human skin flora, mucosae, gastrointestinal tract, genital and urinary systems. Candidiasis encompasses diverse diseases that range from superficial infections of skin and mucosal membranes, to disseminated diseases with profound organ involvement. Deep-seated infections include candidemia, invasive candiadiasis, and peritonitis as well as other entities less frequently diagnosed in the critically ill patient [1].


Antifungal Therapy Minimum Inhibitory Concentration Invasive Candidiasis Liposomal Amphotericin Candida Colonization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Edwards JE (2010) Candida species. In: Mandell GR, Bennett JE, Dolin R (eds) Principles and Practice of Infectious Disease. Chrchill Livingstone Elsevier, Philadelphia, pp 3225–3240Google Scholar
  2. 2.
    Ostrosky-Zeichner L, Pappas PG (2006) Invasive candidiasis in the intensive care unit. Crit Care Med 34: 857–863PubMedCrossRefGoogle Scholar
  3. 3.
    Eggimann P, Bille J, Marchetti O (2011) Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 1: 37PubMedCrossRefGoogle Scholar
  4. 4.
    Blot SI, Vandewoude KH, De Waele JJ (2007) Candida peritonitis. Curr Opin Crit Care 13: 195–199PubMedCrossRefGoogle Scholar
  5. 5.
    Peman J, Canton E, Gobernado M (2005) Epidemiology and antifungal susceptibilities of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24: 23–30PubMedCrossRefGoogle Scholar
  6. 6.
    Almirante B, Rodriguez D, Park BJ, et al (2005). Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43: 1829–1835PubMedCrossRefGoogle Scholar
  7. 7.
    Pfaller MA, Messer SA, Hollis RJ, et al (2009) Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 47: 3185–3190PubMedCrossRefGoogle Scholar
  8. 8.
    Tumbarello M, Sanguinetti M, Trecarichi EM, et al (2008) Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother 62: 1379–1385PubMedCrossRefGoogle Scholar
  9. 9.
    Muñoz P, Sánchez-Somolinos M, Alcalá L, Rodríguez-Créixems M, Peláez T, Bouza E (2005) Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 55: 188–193PubMedCrossRefGoogle Scholar
  10. 10.
    Playford EG, Marriott D, Nguyen Q, et al (2008) Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 36: 2034–2039PubMedCrossRefGoogle Scholar
  11. 11.
    Chow JK, Golan Y, Ruthazer R, et al (2008) Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 36: 1993–1998PubMedCrossRefGoogle Scholar
  12. 12.
    Davis SL, Vazquez JA, McKinnon PS (2007) Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 41: 568–573PubMedCrossRefGoogle Scholar
  13. 13.
    Lin MY, Carmeli Y, Zumsteg J, et al (2005) Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 49: 4555–4560PubMedCrossRefGoogle Scholar
  14. 14.
    Shorr AF, Lazarus DR, Sherner JH, et al (2007) Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 35: 1077–1083PubMedCrossRefGoogle Scholar
  15. 15.
    Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, et al (2010) Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 54: 3149–3154PubMedCrossRefGoogle Scholar
  16. 16.
    Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3: 685–702PubMedCrossRefGoogle Scholar
  17. 17.
    Leroy O, Gangneux JP, Montravers P, et al (2007) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37: 1612–1618CrossRefGoogle Scholar
  18. 18.
    Dupont H, Paugam-Burtz C, Muller-Serieys C, et al (2002) Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 137: 1341–1347PubMedCrossRefGoogle Scholar
  19. 19.
    Sandven P, Qvist H, Skovlund E, Giercksky KE (2002) Significance of Candida recovered from intraoperative specimens in patients with intraabdominal perforations. Crit Care Med 30: 541–547PubMedCrossRefGoogle Scholar
  20. 20.
    Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O (2011) A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 17: 1061–1067PubMedCrossRefGoogle Scholar
  21. 21.
    Magill SS, Swoboda SM, Shields CE, et al (2009) The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Ann Surg 249: 657–665PubMedCrossRefGoogle Scholar
  22. 22.
    Bennett JE (2006) Echinocandins for candidemia in adults without neutropenia. N Engl J Med 355: 1154–1159PubMedCrossRefGoogle Scholar
  23. 23.
    Pérez-Parra A, Muñoz P, Guinea J, Martín-Rabadán P, Guembe M, Bouza E (2009) Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals? Intensive Care Med 35: 707–712PubMedCrossRefGoogle Scholar
  24. 24.
    Pappas PG, Kauffman CA, Andes D, et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503–535PubMedCrossRefGoogle Scholar
  25. 25.
    De Rosa FG, Garazzino S, Pasero D, Di Perri G, Ranieri VM (2009) Invasive candidiasis and candidemia: new guidelines. Minerva Anestesiol 75: 453–458PubMedGoogle Scholar
  26. 26.
    Aguado JM, Ruiz-Camps I, Muñoz P, et al (2011) [Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update.] Enferm Infecc Microbiol Clin 29: 345–361PubMedCrossRefGoogle Scholar
  27. 27.
    Limper AH, Knox KS, Sarosi GA, et al (2011) An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183: 96–128PubMedCrossRefGoogle Scholar
  28. 28.
    Sucher AJ, Chahine EB, Balcer HE (2009) Echinocandins: the newest class of antifungals. Ann Pharmacother 43: 1647–1657PubMedCrossRefGoogle Scholar
  29. 29.
    Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL (2009) Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother 53: 2192–2195PubMedCrossRefGoogle Scholar
  30. 30.
    Pfaller MA, Boyken L, Hollis RJ, et al (2008) In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46: 150–156PubMedCrossRefGoogle Scholar
  31. 31.
    Mora-Duarte J, Betts R, Rotstein C, et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347: 2020–2029PubMedCrossRefGoogle Scholar
  32. 32.
    Kuse ER, Chetchotisakd P, da Cunha CA, et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet 369: 1519–1527PubMedCrossRefGoogle Scholar
  33. 33.
    Reboli AC, Rotstein C, Pappas PG, et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356: 2472–2482PubMedCrossRefGoogle Scholar
  34. 34.
    Pappas PG, Rotstein CM, Betts RF, et al (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45: 883–893PubMedCrossRefGoogle Scholar
  35. 35.
    Garnacho-Montero J, Díaz-Martín A, Cayuela-Dominguez A (2008) Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy. Int J Antimicrob Agents 32 (Suppl 2): S 137–141CrossRefGoogle Scholar
  36. 36.
    DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA (2007) Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 22: 237–244PubMedCrossRefGoogle Scholar
  37. 37.
    Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V (2009) Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 13: R159PubMedCrossRefGoogle Scholar
  38. 38.
    Walsh TJ, Teppler H, Donowitz GR, et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391–1402PubMedCrossRefGoogle Scholar
  39. 39.
    Kullberg BJ, Sobel JD, Ruhnke M, et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366: 1435–1442PubMedCrossRefGoogle Scholar
  40. 40.
    Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36: 630–637PubMedCrossRefGoogle Scholar
  41. 41.
    Khan FA, Slain D, Khakoo RA (2007) Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 27: 1711–1721PubMedCrossRefGoogle Scholar
  42. 42.
    Riddell J 4th, Comer GM, Kauffman CA (2011) Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 52: 648–653PubMedCrossRefGoogle Scholar
  43. 43.
    Rex JH, Bennett JE, Sugar AM, et al (1995) Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 21: 994–996PubMedCrossRefGoogle Scholar
  44. 44.
    Liu CY, Huang LJ, Wang WS, et al (2009) Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect 58: 154–160PubMedCrossRefGoogle Scholar
  45. 45.
    Rodriguez D, Park BJ, Almirante B, et al (2007) Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 13: 788–793PubMedCrossRefGoogle Scholar
  46. 46.
    Nucci M, Anaissie E, Betts RF, et al (2010) Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 51: 295–303PubMedCrossRefGoogle Scholar
  47. 47.
    Almirante B, Rodríguez D, Cuenca-Estrella M, et al (2006) Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 44: 1681–1685PubMedCrossRefGoogle Scholar
  48. 48.
    León C, Ruiz-Santana S, Saavedra P, et al (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34: 730–737PubMedCrossRefGoogle Scholar
  49. 49.
    León C, Ruiz-Santana S, Saavedra P, et al (2009) Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37: 1624–1633PubMedCrossRefGoogle Scholar
  50. 50.
    Magill SS, Swoboda SM, Johnson EA, et al (2006) The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis 55: 293–301PubMedCrossRefGoogle Scholar
  51. 51.
    Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220: 751–758PubMedCrossRefGoogle Scholar
  52. 52.
    Ostrosky-Zeichner L, Sable C, Sobel J, et al (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26: 271–276PubMedCrossRefGoogle Scholar
  53. 53.
    Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC (2011) Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit Care 15: R198PubMedCrossRefGoogle Scholar
  54. 54.
    Charles PE, Castro C, Ruiz-Santana S, León C, Saavedra P, Martín E (2009) Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? Intensive Care Med 35: 2146–2150PubMedCrossRefGoogle Scholar
  55. 55.
    Alam FF, Mustafa AS, Khan ZU (2007) Comparative evaluation of (1, 3)-beta-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis 7: 103PubMedCrossRefGoogle Scholar
  56. 56.
    Ostrosky-Zeichner L, Alexander BD, Kett DH, et al (2005) Multicenter clinical evaluation of the (133)-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41: 654–659PubMedCrossRefGoogle Scholar
  57. 57.
    Pemán J, Zaragoza R (2010) Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses 53: 424–433PubMedCrossRefGoogle Scholar
  58. 58.
    Mohr JF, Sims C, Paetznick V, et al (2011) Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 49: 58–61PubMedCrossRefGoogle Scholar
  59. 59.
    Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL (2005) Evaluation of a (1> 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43: 5957–5962PubMedCrossRefGoogle Scholar
  60. 60.
    Pemán J, Zaragoza R, Quindós G, et al (2011) Clinical factors associated with a Candida albicans germ tube antibody positive test in intensive care unit patients. BMC Infect Dis 11: 60PubMedCrossRefGoogle Scholar
  61. 61.
    Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until obtaining positive blood culture results: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 49: 3640–3645PubMedCrossRefGoogle Scholar
  62. 62.
    Garey KW, Rege M, Pai MP (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multicenter study. Clin Infect Dis 43: 25–31PubMedCrossRefGoogle Scholar
  63. 63.
    De Rosa FG, Garazzino S, Pasero D, Di Perri G, Ranieri VM (2009) Invasive candidiasis and candidemia: new guidelines. Minerva Anestesiol 75: 453–458PubMedGoogle Scholar
  64. 64.
    Montravers P, Dupont H, Gauzit R, et al (2006) Candida as a risk factor for mortality in peritonitis. Crit Care Med 34: 646–652PubMedCrossRefGoogle Scholar
  65. 65.
    Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31: 752–757PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • J. Garnacho-Montero
  • A. Díaz-Martín
  • J. A. Márquez-Vácaro

There are no affiliations available

Personalised recommendations